IngentaConnect Paliperidone Extended Release

Authors: Yang, Lily P.H.¹; Plosker, Greg L.¹

Source: CNS Drugs, Volume 21, Number 5, 2007 , pp. 417-425(9)

Abstract:

▴ Paliperidone extended release (ER) is an atypical antipsychotic that is administered orally once daily to provide consistent plasma drug concentrations over 24 hours in adult patients with schizophrenia.

▴ In four well controlled trials, once-daily administration of paliperidone ER 3-12mg over 6 weeks was more effective than placebo in reducing the positive and negative symptoms experienced by adult patients with schizophrenia, including elderly individuals aged ≥65 years.

▴ Patients with schizophrenia treated with paliperidone ER achieved greater improvement in clinically relevant measures of personal and social functioning and disease severity than those who received placebo.

▴ In another well controlled trial, paliperidone ER demonstrated superior efficacy to placebo in preventing the recurrence of schizophrenia symptoms. In patients who experienced a recurrence, time to recurrence was delayed with paliperidone ER compared with placebo administration.

▴ Paliperidone ER 3-12 mg/day for 6 weeks was generally well tolerated by patients with schizophrenia in clinical trials.

Keywords: Adis Drug Profiles; Antipsychotics; Paliperidone; Schizophrenia

Document Type: Research article

Affiliations: 1: Wolters Kluwer Health | Adis, Auckland, New Zealand, an editorial office of Wolters Kluwer Health, Conshohocken, Pennsylvania, USA

The full text article is available for purchase

$54.95 plus tax